| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| Other Sizes |
| Targets |
The compound targets endogenous metabolic pathways as an endogenous metabolite. It acts as a competitive inhibitor of the enzyme succinate dehydrogenase. It is used as a precursor to produce (trimethylsilyl)ethyl malonate, which is utilized to prepare beta-ketoesters by acylation. The compound may also interact with metabolic enzymes involved in the malonate pathway.
|
|---|---|
| ln Vitro |
3-Ethoxy-3-oxopropanoic acid potassium promotes plant growth, suggesting potential bioactivity in plant systems. As an endogenous metabolite, it participates in normal metabolic processes. Its inhibitory activity against succinate dehydrogenase indicates potential effects on the tricarboxylic acid cycle and energy metabolism. Further in vitro studies are needed to characterize its activity in mammalian systems.
|
| ln Vivo |
In vivo activity has been primarily reported in plant systems, where the compound promotes growth. No significant in vivo pharmacological activity has been documented in animal models. The compound is considered an endogenous metabolite and may be involved in normal physiological processes. Its role as a succinate dehydrogenase inhibitor suggests potential metabolic effects in vivo.
|
| Enzyme Assay |
In vitro enzyme assays for succinate dehydrogenase inhibition typically involve incubating the enzyme with varying concentrations of the compound (0.1-10 mM) in phosphate buffer at pH 7.4. Enzyme activity is measured spectrophotometrically by following the reduction of 2,6-dichlorophenolindophenol (DCPIP) or by monitoring succinate-dependent oxygen consumption. The competitive inhibition constant (Ki) is determined by Lineweaver-Burk plot analysis. Malonate derivatives are classic competitive inhibitors of succinate dehydrogenase.
|
| Cell Assay |
For in vitro cell assays, cells are cultured in medium supplemented with 3-Ethoxy-3-oxopropanoic acid potassium at concentrations ranging from 10 µM to 10 mM. Cell viability is assessed by MTT assay after 24-72 hours of treatment. Metabolic effects are evaluated by measuring oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) using Seahorse analyzers. Intracellular succinate and malonate levels are quantified by LC-MS/MS to assess metabolic flux through the TCA cycle.
|
| Animal Protocol |
For in vivo animal studies, the compound is typically administered to rodents via oral gavage or intraperitoneal injection at doses of 10-100 mg/kg. Blood samples are collected at various time points for pharmacokinetic analysis. Tissue distribution and metabolic effects are assessed by measuring succinate dehydrogenase activity in liver and muscle homogenates. Plant growth promotion studies involve application to soil or foliar spray at concentrations of 0.1-1 mM.
|
| ADME/Pharmacokinetics |
3-Ethoxy-3-oxopropanoic acid potassium is highly soluble in water (>34 mg/mL). As a small molecule (MW 170.21), it is expected to be readily absorbed and distributed throughout the body. The compound is metabolized through ester hydrolysis to release malonate, which enters the TCA cycle. It is stable at 4°C sealed storage and in solvent at -80°C for 6 months. Elimination is primarily via renal excretion as malonate.
|
| Toxicity/Toxicokinetics |
The compound is considered to have low toxicity as an endogenous metabolite. No significant acute toxicity has been reported. For research use only, not for human therapeutic applications. The safety profile is expected to be similar to that of malonate salts, which are generally well-tolerated at moderate doses. Skin absorption may occur; standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
3-Ethoxy-3-oxopropanoic acid potassium (CAS# 6148-64-7) is primarily a chemical intermediate and research reagent. It has not been investigated in clinical trials nor approved as a therapeutic drug. The compound is classified as an endogenous metabolite and is used in metabolic research and organic synthesis. It has applications in plant science research for growth promotion studies. No information is available on its use in humans.
|
| Molecular Formula |
C5H7KO4
|
|---|---|
| Molecular Weight |
170.21
|
| Exact Mass |
169.998
|
| CAS # |
6148-64-7
|
| PubChem CID |
3446434
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
237.2ºC at 760 mmHg
|
| Melting Point |
194 °C (dec.)(lit.)
|
| Flash Point |
100.8ºC
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
10
|
| Complexity |
123
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC(=O)CC(=O)[O-].[K+]
|
| InChi Key |
WVUCPRGADMCTBN-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C5H8O4.K/c1-2-9-5(8)3-4(6)7;/h2-3H2,1H3,(H,6,7);/q;+1/p-1
|
| Chemical Name |
potassium;3-ethoxy-3-oxopropanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8751 mL | 29.3755 mL | 58.7510 mL | |
| 5 mM | 1.1750 mL | 5.8751 mL | 11.7502 mL | |
| 10 mM | 0.5875 mL | 2.9375 mL | 5.8751 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
